The use of mathematical models for personalization of cancer therapies and raising hypothesis of potential clinical impact is an emerging topic in the interface between mathematics and oncology. Here we put forward a mathematical model describing the response of low-grade (WHO grade II) oligodendrogliomas (LGO) to temozolomide (TMZ). The model described the longitudinal volumetric dynamics of tumor response to TMZ of a cohort of 11 LGO patients treated with TMZ. After finding patient-specific parameters, different therapeutical strategies were tried computationally on the 'in-silico twins' of those patients. Chemotherapy schedules with larger-than-standard rest periods between consecutive cycles had either the same or better long-term efficacy than the standard 28-day cycles. The results were confirmed in a large virtual clinical trial including 2000 patients. These long-cycle schemes would also have reduced toxicity and defer the appearance of resistances.
Introduction

1
Oligodendrogliomas (ODGs) are low-incidence glial tumors, affecting mostly young 2 adults. They are slowly growing, infiltrative tumors with isocitrate dehydrogenase 1 or 3 2 mutations and codeletion of chromosomal arms 1p and 19q. Grade II ODGs (LGO) 4 are well differentiated tumors with a low mitotic index [1] . In spite of the long median 5 patient survival, they are incurable currently [2] . 6 Many ODG patients present few neurological symptoms for extended periods of 7 time. The decision on the specific combination of therapies to be used on each patient 8 is based on the qualitative consideration of different variables including age, tumor 9 grade, performance status and tumor location [3] . Radiation therapy (RT) is beneficial 10 for patients in terms of survival, but its timing has been the subject of debate [4] .
11
Regarding chemotherapy (CT), temozolomide (TMZ), an oral alkylating agent, has 12 a favourable toxicity profile [5] and can contribute to reduction in seizure frequency in 13 low-grade glioma (LGG) patients [6] . Phase II trials have demonstrated its effectivity 14 against LGGs [7] [8] [9] . Also, neoadjuvant CT given to surgically unresectable tumors has 15 allowed subsequent gross total resection in some cases [10] , which is of relevance when 16 the tumour is highly infiltrative or located in eloquent areas. Thus, prolonged 17 TMZ treatment is a relevant option either as up-front or as adjuvant treatment.
18
Clinical trials have shown a similar efficacy of TMZ vs RT for 1p/19q-codeleted 19 tumors [11, 12] . Also, RT is associated with late neurocognitive toxicity. Thus CT is 20 frequently used as first-line treatment for ODG patients. In that context, relevant 21 questions arise such choice of the chemotherapy regimen and the optimal number of 22 cycles to be prescribed. 23 Mathematical models have potential to help in finding optimized treatment 24 schedules/combinations improving survival and/or reducing toxicity [13, 14] . Once the 25 base mathematical model is set, patient-specific parameters can be obtained from data. 26 That provides an 'in-silico twin' [15] allowing computational studies that could be 27 beneficial for real patients.
28
Materials and methods
29
Patients
30
82 patients diagnosed of LGG (biopsy/surgery confirmed astrocytoma, 
35
Of that patient population, we selected 1p/19q-codeleted tumors (thus LGOs 36 according to the 2016 WHO classification) treated with at least three cycles of TMZ, 37 having no previous RT treatment and no other treatment given in the period of study.
38
Only 16 patients satisfied these criteria. Of them 3 (19%) did not respond to TMZ 39 and 2 (12%) responded initially but progressed during treatment to anaplastic forms.
40
Thus 11 (69%) oligodendroglioma patients responded to the therapy, did not display 41 any signs of malignant transformation and were used for this study. 
, following the standard practice [16] . To estimate 49 the error of the methodology we took a different set of glioma patients from another 50 study [17] and compared their volumes computed accurately using a semi-automatic 51 segmentation approach with those computed using the ellipsoidal approximation.
52
Mean differences were 18%, that was the reference level used for the error in the 53 volume computations.
54
Mathematical model
55
In this paper we considered LGOs in a simplified way as composed of two tumor cell 56 compartment. The first one was the tumor cell population P (t), assumed to grow to death through different 'programmes' [18] [19] [20] . We put together the different 60 processes into two groups, each described by a term in our equations. The first one 61 was early death accounting for necrosis, autophagy and drug-induced apoptosis with 62 rate α 1 . The second one was delayed death through mitotic catastrophe with rate α 2 .
63
In radiotherapy, the second process is the leading one [21] , but not in cytotoxic 64 chemotherapy treatments [19, 20] . The drug concentration in tissue was described by Figure 1 shows a schematic description of the model. The equations were: 
Drug administration was described as impulses for the LGG patients [22] . However, many patients die when the tumor volume is smaller [15] . 79 The most typical chemotherapy schedule consists of cycles of 28 days with five To calculate the rate of drug decay 82 λ we followed the same methodology as in Ref. [34] , using values of TMZ half-life C max = 0.6 µg/ml as in Ref. [34] .
94
The parameters α 1 , α 2 and ρ are expected to depend strongly on the tumor growth 95 rate and sensitity to the therapy and will be considered to be adjustable parameters.
96
These parameters, together with the initial population value P (0) were fit for each 97 patient longitudinal volumetric data using the library fmincon in the scientific 98 software package Matlab (R2017b, The MathWorks, Inc., Natick, MA, USA). Table 1 99 summarizes the main characteristics and parameter values found for patients included 100 in the study. Since Eqs. (1) are a system of nonlinear ordinary differential equations, parameters are listed in Table 1 .
107
Virtual clinical trials
108
To study the effect of the different treatment schedules on patient survival we designed 109 virtual trials. A number of patients was generated by a random choice of the 110 parameters. Uniform distributions were taken for the parameters in the most 111 representative region of the parameter space obtained from Table 1 :
[0.1, 0.75] ml/µg day, P (0) ∈ [20, 200] , K ∈ [300, 550] cm 3 . Virtual trials were run using 114 Matlab 2017b parallel computing toolbox using a parallel algorithm on a 64 GB 115 memory 2.7 GHz 12-core Mac pro workstation under OS X 10.14.
116
Results
117
The mathematical model describes the general features of LGO 118 response to temozolomide 119 Typical LGG longitudinal growth and response to therapy consists of four stages (see The model was then used as a discovery platform to test alternative treatment regimes 144 in-silico for the patients included in the study. As a first test, we enlarged the time In the case of large tumors, whose size was comparable to K and thus the 154 nonlinear term in Eq. (1) played a relevant role, differences between the schemes were 155 observed favoring long-cycle schemes (see e.g. Fig. 4(b) ). As a second series of tests, we explored alternative treatment regimes based on the 157 28-day cycle. A first regime consisted in 5 doses given following a 1-day on, 1-day off 158 scheme during the first 10 days of the cycle. A second alternative was distributing 159 doses evenly within the cycle duration, i.e. giving a single dose every 4 days. Both 160 treatment regimes led to tumor volumetric evolutions overlapping with the ones of the 161 standard treatment (e.g., those depicted in Figure 3 ).
162
Several virtual trials were conducted as described in the 'Methods' section.
163
Benefits in median survival were found for the long-cycle strategies that were 164 dependent on the parameter K. Long-cycle treatment schemes were never inferior in 165 terms of survival to the standard ones. Indeed, the differences found between survival 166 curves for long-cycle schedules versus the standard ones were never statistically 167 significant (p < 0.05) according to the log-rank test. Table 1 ). Treatment was effective for all patients 172 included. However, since there is no standardized protocol for chemotherapy in ODG 173 patients, the decision to stop treatment was taken depending on toxicitity, physician 174 and patient preferences, etc.
175
On the basis of our previous results we explored the potential effectiveness of 176 standardizing treatment for all of the virtual patients consisting of an induction part 177 of five cycles given monthly to reduce substantially the tumor burden followed by a 178 consolidation of 12 cycles given every three months. This treatment scheme was based 179 on the idea that TMZ cycles given every three months should be well tolerated and 180 allow for this long schedule. Moreover, having a first induction part would result in an 181 initial larger tumor volume reduction than for the long-cycle schemes alone. Results
182
are summarized in Figure 5 . Survival improvements, many of them substantial, were 183 obtained for the in-silico twins of the patients included in the study (Median 5.69 184 years, range: 0.67 to 68.45 years, see Fig. 5(a) ). Virtual patients for which the number 185 of cycles was larger (patients 3, 6, 7, 8 and 10) than those received by the real one (see 186  Table 1 ) had larger survival benefits. Also for most patients there was a substantial 187 volumetric reduction in relation to the one achieved for the real patient under the 188 number of cycles given by Table 1 (see Fig. 5(b) ). Results of the virtual trial comparing a standard chemotherapeutic approach for LGO versus the proposed scheme. Shownare the Kaplan-Meir plots for both arms. In the first arm (blue), virtual patients received a random number of cycles in the range spanned by the real patients (between 5 and 18 sequential cycles with the standard 1 month spacing). The same virtual patients received the proposed scheme (5 cycles induction given monthly + 12 cycles consolidation given every 3 months). Patients were assumed to die when tumors reached a volume of 280 cm 3 and those alive after 25 years were considered as censored events. quiescent cells, and the drug decay time in brain tissue was fitted to be of the order of 211 several months, a value out of the reasonable range. This is in striking contrast with 212 the value used here inferred from realistic data of a few hours. Bogdanska et al. [34] Ref. [32] while having all parameter values in meaningful ranges.
217
For all virtual patients the simulations showed interesting features: (i) Tumor the two patients receiving longer more intensive treatments in real life, the volumetric 236 reductions obtained in-silico were smaller than the ones observed. In spite of that, 237 patients survived longer in the simulations. Indeed, three patients received in real life 238 the same or more CT cycles than in our proposed scheme, but our less toxic scheme 239 resulted in longer survival in the computer simulations. The results were confirmed on 240 a virtual trial including 2000 patients and comparing 'in-silico' both treatment arms.
241
Interestingly, all long-cycle regimes studied were independent on the time point at 242 which the doses were given, i. 
